The rationale for the current boom in anti-TNFα treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFα and minimise hazards?

Annals of the Rheumatic Diseases

Volumn 58, Issue SUPPL. 1, 1999, Pages

  Feldmann, Marc ^a   Bondeson, Jan ^a   Brennan, Fionula M ^a   Foxwell, Brian M J ^a   Maini, Ravinder N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; AUTOIMMUNE DISEASE; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG INDICATION; GENE TARGETING; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; MACROPHAGES; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032747020     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Goeddel DV, Yelverton E, Ullrich A, et al. Human leukocyte Interferon produced by E. coli is biologically active. Nature 1980;287:411-16.
2. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumor necrosis factor: precursor structure expression and homology to lymphotoxin. Nature 1984;312:724-9.
3. Taniguchi T, Matsui H, Fujita T, et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 1983;302:305-10.
4. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996;14:397-440.
5. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin Exp Immunol 1988;73:449-55.
6. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;ii:244-7.
7. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur J Immunol 1991;21: 2575-9.
8. Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti-TNFα antibody with the IL-1 receptor antagonist. Eur Cytokine Network 1995,6:225-30.
9. Saxne T, Palladino MA, Jr, Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor a but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041-5.
10. Brennan FM, Gibbons D, Cope AP, Reed B, Maini RN, Feldmann M. TNF-α and TNF receptor expression and regulation in rheumatoid arthritis. In: Balint G, Gomor B, Hodinka L, eds. Rheumatology, state of the art. Amsterdam: Elsevier Science Publishers, 1992:115-17.
11. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor a in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
12. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumour necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992;89:7375-9.
13. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Nat Acad Sci USA 1992;89:9784-8.
14. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992;77:510-14.
15. Elliott MJ, Maini RN, Fcldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNFα. Arthritis Rheum 1993;36:1681-90.
16. Ellioti MJ, Maini RN, Feldmann M, et al. Randomised double blind comparison of a chimaeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
17. Rankin ECC, Choy EHS, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CD571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
18. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
19. Cutolo M, Kirkham B, Bologna C, et al. Loading/ maintenance doses approach to neutralization of TNF by Lenercept (TN-FR55-IgG1, Ro45-2081) inpatients with rheumatoid arthritis treated for 3 months: results of a double-blind placebo controlled phase II trial. Arthritis Rheum 1996;39:S243.
20. Schattenkirchner M, Kruger K, Sander O, et al. Efficacy and tolerability of weekly subcutaneous injections of the fully human anti THF antibody D2E7 in patients with rheumatoid arthritis - Results of a phase 1 study. Arthritis Rheum 1998;41:S57.
21. Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997;94:8093-8.
22. Foxwell BMJ, Browne K, Bondeson J, et al. Efficient adenoviral infection with TκBα reveals that TNFα production in rheumatoid arthritis is NF-κB dependent. Proc Natl Acad Sci USA 1998;95:8211-15.
23. Bondeson J, Brown KA, Brennan FM, Foxwell BMJ, Feldmann M. Selective regulation of cytokine induction by adenoviral gene transfer of IκBα into human macrophages: LPS induced but not zymosan induced, pro-inflammatory cytokines are inhibited, but IL-10 is NFκb independent. J Immunol 1999;162:2939-45.
24. Wang C-Y, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996;274:784-7.
25. Bondeson J, Foxwell BMJ, Brennan FM, Feldmann M. Defining therapeutic targets by using adenovirus: blocking MF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc Natl Acad Sci USA 1999;96:5668-73.
26. Fini ME, Cook JR, Mohan R, Brinckerhoff CE. Regulation of matrix metalloproteinase gene expression. In: Parks WC, Mecham RP, eds, Matrix metalloproteinases. San Diego: Academic, 1998:299-356.
27. Smith CA, Davis T, Anderson D, et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990;248:1019-23.